Healthcare - Biotechnology - NASDAQ - US
$ 53.78
-2.92 %
$ 3.07 B
Market Cap
4.61
P/E
CASH FLOW STATEMENT
-296 M
OPERATING CASH FLOW
240 M
INVESTING CASH FLOW
5.43 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Agios Pharmaceuticals, Inc.
| Net Income | -352 M |
| Depreciation & Amortization | 6.62 M |
| Capital Expenditures | -999 K |
| Stock-Based Compensation | 44.8 M |
| Change in Working Capital | -19.1 M |
| Others | 24.6 M |
| Free Cash Flow | -297 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||
| Net Income | (352.1) | (231.8) | (356.5) | (327.4) | (411.5) | (346.0) | (314.7) | (198.5) | (117.7) | (53.5) | (39.4) | (20.1) | (23.7) |
| Depreciation & Amortization | 6.6 | 8.6 | 9.2 | 10.0 | 8.1 | 7.2 | 6.4 | 5.7 | 3.3 | 1.4 | 1.4 | 1.2 | 0.8 |
| Deferred Income Tax | 0 | 0 | (86.3) | 3.0 | (2.1) | 0 | 0 | 0 | 0 | 0 | 3.8 | 6.7 | (10.7) |
| Stock Based Compensation | 44.8 | 49.3 | 53.5 | 61.6 | 72.4 | 73.4 | 47.8 | 42.1 | 32.0 | 11.5 | 3.0 | 0.7 | 0.4 |
| Other Operating Activities | 23.7 | (119.1) | 9.5 | 19.5 | 8.5 | (3.8) | 29 K | 0.8 | 0.6 | 0.5 | 0.3 | 0.3 | 0.4 |
| Change in Working Capital | (19.1) | (16.4) | (36.8) | (71.0) | (46.0) | (35.1) | (24.8) | 188.5 | 4.9 | (19.3) | (25.6) | (38.4) | 17.6 |
| Cash From Operations | (296.1) | (309.5) | (407.3) | (290.8) | (370.6) | (304.4) | (285.2) | 38.6 | (76.9) | (59.4) | (56.4) | (49.5) | (15.2) |
| INVESTING CASH FLOW | |||||||||||||
| Capital Expenditures | (1.0) | (4.9) | (5.7) | (14.9) | (12.2) | (7.0) | (4.6) | (9.9) | (20.2) | (2.2) | (1.3) | (1.5) | (1.9) |
| Other Items | 240.6 | 248.1 | 1 254.5 | 90.7 | 103.6 | (266.8) | (53.3) | (109.4) | 148.5 | (331.1) | (85.9) | 24.5 | (20.5) |
| Cash From Investing Activities | 239.6 | 243.3 | 1 248.8 | 75.7 | 91.4 | (273.8) | (57.9) | (119.3) | 128.3 | (333.3) | (87.2) | 23.0 | (22.4) |
| FINANCING CASH FLOW | |||||||||||||
| Common Stock Repurchased | 0 | 0 | (802.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | (0.3) | (0.6) | (0.3) | (0.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.4 | 2.7 | 37.3 | 261.9 | 12.5 | 29.8 | 14.9 | 7.6 | 6.4 | 1.6 | (2.2) | 0.1 | 77.4 |
| Cash From Financing Activities | 5.4 | 2.4 | (765.8) | 261.5 | 289.6 | 546.0 | 285.1 | 169.8 | 6.4 | 335.2 | 123.9 | 0.1 | 77.4 |
| CHANGE IN CASH | |||||||||||||
| Net Change In Cash | (51.1) | (63.9) | 75.7 | 46.5 | 10.4 | (32.2) | (58.0) | 89.0 | 57.7 | (57.5) | (19.7) | (26.4) | 39.8 |
| FREE CASH FLOW | |||||||||||||
| Free Cash Flow | (297.1) | (314.4) | (413.1) | (305.7) | (382.8) | (311.4) | (289.9) | 28.6 | (97.1) | (61.6) | (57.7) | (51.0) | (17.1) |